Drug Profile
Zimlovisertib - Pfizer
Alternative Names: PF-06650833; PF-6650833Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Yale University
- Class Amides; Anti-infectives; Anti-inflammatories; Antirheumatics; Fluorinated hydrocarbons; Isoquinolines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 pneumonia; COVID-19 respiratory infection; Rheumatoid arthritis
- No development reported Lupus vulgaris
- Discontinued Hidradenitis suppurativa
Most Recent Events
- 10 Sep 2023 Pharmacokinetics and adverse events data from a phase I trial in volunteers presented at the 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023)
- 08 Feb 2022 Discontinued - Phase-II for Hidradenitis suppurativa in Australia (PO) (Pfizer pipeline, May 2022)
- 08 Feb 2022 Discontinued - Phase-II for Hidradenitis suppurativa in Canada (PO) (Pfizer pipeline, May 2022)